Taliglucerase alfa is an enzyme replacement therapy approved for treatment of Gaucher disease (GD) in children and adults in several countries. This multicenter extension study assessed the efficacy and safety of taliglucerase alfa in pediatric patients with GD who were treatment-naïve (n = 10) or switched from imiglucerase (n = 5). Patients received taliglucerase alfa 30 or 60 U/kg (treatment-naïve) or the same dose as previously treated with imiglucerase every other week. In treatment-naïve patients, taliglucerase alfa 30 and 60 U/kg, respectively, reduced mean spleen volume (−18.6 multiples of normal [MN] and −26.0 MN), liver volume (−0.8 MN and −0.9 MN), and chitotriosidase activity (−72.7% and −84.4%), and increased mean Hb concentration (+2.0 g/dL and +2.3 g/dL) and mean platelet count (+38,200/mm 3 and +138,250/mm 3 ) from baseline through 36 total months of treatment. In patients previously treated with imiglucerase, these disease parameters remained stable through 33 total months of treatment with taliglucerase alfa. Most adverse events were mild/moderate; treatment was well tolerated. These findings extend the taliglucerase alfa safety and efficacy profile and demonstrate longterm clinical improvement in treatment-naïve children receiving taliglucerase alfa and maintenance of disease stability in children switched to taliglucerase alfa. Treatment was well-tolerated, with no new safety signals. This study is registered at www.clinicaltrials.gov as NCT01411228.
Introduction
Gaucher disease (GD) is a rare lysosomal storage disorder resulting from mutations in the gene for the enzyme β-glucocerebrosidase [1] . Deficiency of β-glucocerebrosidase activity in macrophages and other cell types results in the accumulation of glucocerebrosidase in lysosomes, leading to pathology, including splenomegaly, hepatomegaly, anemia, and thrombocytopenia [2] . Patients who are diagnosed with Type 1 GD during childhood, particularly during early childhood, tend to have more severe disease manifestations, more rapid disease course, and greater burden of disease [2] [3] [4] [5] [6] [7] .
For patients with Type 1 (non-neuronopathic) GD, development of enzyme replacement therapy (ERT) constitutes a major advancement in care and has altered the natural disease course [1, 2] . ERT is recommended for children with GD, and early treatment may decrease the risk of irreversible pathology [6, 7] .
Taliglucerase alfa is an ERT approved for adults with Type 1 GD in the United States, Israel, Brazil, Chile, Australia, Canada, and other countries and for pediatric patients in the United States, Israel, Australia, and Canada, and for hematologic manifestations in pediatric patients with Type 3 GD in Canada. Taliglucerase alfa is the first plant cell-expressed recombinant therapeutic protein approved by the US Food and Drug Administration for use in humans. This agent is produced in a plant cell suspension in disposable bioreactors [8] free of mammalian components [8] [9] [10] .
Taliglucerase alfa is the only ERT for GD that has been tested prospectively in pediatric-focused studies. Prospective clinical studies have investigated the safety and efficacy of taliglucerase alfa in pediatric patients with GD. Study PB-06-005 assessed the efficacy and safety of taliglucerase alfa at 2 dose levels, 30 U/kg and 60 U/kg, in treatmentnaïve children with GD (n = 11) during 12 months of treatment [11] . Findings showed clinically significant improvements in spleen and liver volumes, Hb levels, platelet counts, and chitotriosidase activity [11] . Study PB-06-002 assessed the safety and efficacy of switching from imiglucerase to the same dose of taliglucerase alfa in pediatric (n = 5) and adult (n = 26) patients with stable GD [12] . Findings indicated that all patients, including the pediatric patients, remained clinically stable through 9 months of treatment following the switch from imiglucerase to taliglucerase alfa [12] . Pediatric patients who completed PB-06-005 and PB-06-002 were eligible to enroll in extension study PB-06-006. Here, we report the long-term safety and efficacy findings for pediatric patients receiving taliglucerase alfa in study PB-06-006 through 36 months of treatment.
Materials and methods

Study design
PB-06-006 (NCT01411228) was a multicenter extension study designed to evaluate the long-term efficacy and safety of taliglucerase alfa in patients with GD who were 2 to b18 years old and had completed PB-06-005 (treatment naïve; NCT01132690) or PB-06-002 (treatment switch from imiglucerase to taliglucerase alfa; NCT00712348). Protocol details for PB-06-005 and PB-06-002 have been reported previously [11, 12] . PB-06-005 was a double-blind study that enrolled treatment-naïve patients 2 to b18 years old and randomized them to 12 months of taliglucerase alfa 30 or 60 U/kg. PB-06-002 was an open-label study that enrolled adult and pediatric patients who were identified as having a stable clinical GD presentation and had been receiving ERT for ≥ 2 years on a stable maintenance dose of imiglucerase for 6 months; these patients were switched from imiglucerase to taliglucerase alfa at the same dose and received taliglucerase alfa for 9 months.
In PB-06-006, patients continued receiving taliglucerase alfa every other week for up to an additional 24 months of treatment at the same dose the patient received in the previous taliglucerase alfa study. Patients from PB-06-005 received up to 36 total months of treatment (12 months of double-blind treatment in PB-06-005 followed by 12 months of double-blind treatment in PB-06-006 and an additional 12 months of open-label treatment in PB-06-006), and patients from PB-06-002 received up to 33 total months of open-label treatment. Based on results from previous and current studies confirming the efficacy and safety of taliglucerase alfa and to ease the burden of clinical studies for pediatric patients, the sponsor decided to close the extension study early. Two patients who switched from imiglucerase (30-233 and 92-232) had not completed 24 months of treatment in PB-06-006 at the time of study closure; they completed 18 months of treatment in study PB-06-006 (27 total months of treatment) and continued treatment under a compassionate use program.
This study was conducted in accordance with Good Clinical Practice guidelines and according to the International Council for Harmonisation Harmonized Tripartite Guideline and all local regulations. The protocol and informed consent form were reviewed and approved by the appropriate institutional review board/ethics committee associated with the study site. Informed written consent was obtained from each patient and/or the parent or guardian.
Patients
Inclusion criteria for PB-06-006 were completion of PB-06-005 or PB-06-002 and written informed consent. Inclusion criteria for PB-06-005 and PB-06-002 have been published [11, 12] . Exclusion criteria were presence of severe complex neurological signs and symptoms characteristic of neuronopathic GD other than long-standing oculomotor gaze palsy; any medical, emotional, behavioral, or psychological condition that would interfere with study participation; and current use of another investigational agent.
Efficacy assessments
Spleen and liver volumes were measured using a volumetric MRI technique employing automatic segmentation software methodology, which allows for lower variability and more precise monitoring of changes over time than traditional, fully manual methods [13] . Volume was calculated in multiples of normal (MN), where normal spleen volume is 2 mL/kg and normal liver volume is 25 mL/kg. Hb concentration and platelet count measurements were performed by local laboratories. Anemia was defined as a serum Hb level b 11.0 g/dL for patients 0.5 to b5 years old, b 11.5 g/dL for patients 5 to b 12 years old, b12.0 g/dL for patients 12 to b 15 years old, b12.0 g/dL for female (b11.0 g/dL if pregnant), and b 13.0 g/dL for male patients ≥ 15 years old. Assays for chitotriosidase activity and levels of CCL18 were performed by a central laboratory (Academic Medical Center, Amsterdam, The Netherlands). Due to assay variability and for biomarker measurement consistency, the baseline samples obtained during the original studies PB-06-005 or PB-06-002 were re-run with the on-treatment samples for each time point in study PB-06-006 for chitotriosidase activity and CCL18 concentration. The last biomarker measurement was at 30 total months of treatment for patients switched from imiglucerase to taliglucerase alfa.
Exploratory end points included changes in height and weight, bone age (by plain radiography of the left hand and wrist), occurrence of bone crises (included in safety analysis), change in pubertal status (by Tanner stage), and change in quality of life in patients from PB-06-005 using the Child Health Questionnaire™ Parent Form-28 [14] .
Safety
Safety assessments included adverse events (AEs), vital signs, laboratory tests, and anti-taliglucerase alfa antibodies performed as previously described [11] . Clinical signs and symptoms reported during the study were evaluated to identify possible anaphylaxis in a post hoc analysis based on Sampson-defined criteria for determining anaphylaxis [15] . Bone events, including bone crises, were included in the analysis of AEs. The AEs described herein are those with onset that occurred during PB-06-006.
Statistical analysis
For each parameter, efficacy analyses included patients for whom data were available at each time point. Time points for efficacy assessments were counted continuously from baselines in PB-06-005 or PB-06-002 through PB-06-006 and are denoted by total months of taliglucerase alfa treatment relative to baseline.
Descriptive statistics for continuous variables, sample size (n), and mean and its standard error (SE), standard deviation, median, and range were determined; for categorical variables, count and percentages were calculated. Because of the small size of the study, inferential statistics were not performed for testing the change from baseline and/or for comparison between or among treatment groups. For continuous values that are summarized (e.g., demographics), standard deviation is provided; SE is presented for continuous values that may be compared (e.g., baseline and on-treatment values).
Results
Patients
The patient disposition is shown in Fig. 1 . Of the 11 patients who completed PB-06-005 (treatment-naïve), 1 patient (10-5003) did not enroll in PB-06-006 because of worsening of a disease characteristic, cardiac valve involvement requiring intervention; this patient continued taliglucerase alfa treatment in a compassionate use program. Of the 10 patients from PB-06-005 who enrolled in PB-06-006, 9 completed 36 total months of treatment; 1 patient (10-5001; 60 U/kg) withdrew voluntarily after 66 total infusions in studies PB-06-005 and PB-06-006 for personal reasons (parent was unhappy with the child's growth). All 5 patients who were previously treated with imiglucerase and completed PB-06-002 enrolled in PB-06-006; of these, 1 patient (30-231) was lost to follow-up after 59 total infusions in studies PB-06-002 and PB-06-006. Because the study was closed prematurely, 2 patients (30-233, 92-232) completed 18 months of treatment in PB-06-006 (27 total months of treatment with taliglucerase alfa) and entered into a compassionate use program. Patient demographics and baseline disease characteristics are listed in Tables 1 and 2 , respectively. 
Extent of exposure
Organ volumes
Mean and individual spleen volumes for treatment-naïve patients improved over 36 months of therapy with taliglucerase alfa in both Table 2 ). In patients receiving 30 U/kg, mean spleen volume decreased from 23.9 MN at baseline to 9.0 MN at 36 months; in patients receiving 60 U/kg, mean spleen volume decreased from 29.4 MN to 6.6 MN. Spleen volumes for the patients who switched from imiglucerase improved or remained stable through 33 months of therapy (Fig. 2b , Table 2 ). Mean and individual liver volumes for treatment-naïve patients improved during the 36 months of treatment with taliglucerase alfa in both dose groups (Fig. 2c, Table 2 ). Mean liver volume was 1.9 MN at baseline and 1.3 MN at 36 months for patients receiving 30 U/kg and 2.2 MN at baseline and 1.5 MN at 36 months for patients receiving 60 U/kg. In the patients who switched from imiglucerase, liver volumes remained stable (Fig. 2d, Table 2 ).
Hematologic parameters
In treatment-naïve patients, mean and individual Hb levels improved over 36 months of treatment with taliglucerase alfa (Fig. 3a, Notes to Table: CCL18, chemokine (C-C motif) ligand 18; Hb, hemoglobin; MN, multiples of normal, where normal spleen volume is 2 mL/kg times body weight (kg) and normal liver volume is 25 mL/kg times body weight (kg); SE, standard error. For explanation of patient numbers, refer to Figs. 2-4 (legends).
a Baseline is that from the study the patient participated in before enrolling in PB-06-006 (i.e., PB-06-005 for treatment-naïve patients and PB-06-002 for the patients who switched from imiglucerase). b For treatment-naïve patients, values represent those achieved after 36 total months of treatment; for patients switched from imiglucerase to taliglucerase alfa, values represent those achieved after 33 total months of treatment for all parameters except chitotriosidase and CCL18, which was 30 total months of treatment. c Absolute change and percent change were calculated based on baseline and end-of-study values for patients remaining at the end of the study. d Due to assay variability, the baseline samples obtained during original studies PB-06-002 and PB-06-005 were re-run with the on-treatment samples. Table 2 ). Mean Hb concentration was 11.2 g/dL at baseline and 13.2 g/dL at 36 months for patients receiving 30 U/kg and 10.6 g/dL at baseline and 12.7 g/dL for patients receiving 60 U/kg. Of the 10 treatment-naïve patients, 7 had anemia at baseline. In this subset of patients with anemia, 6 completed 36 months of treatment; the mean (SE) increase in Hb concentration from baseline to 36 months was + 2.5 (0.7) g/dL (+ 26.9% [11.0%], n = 3) for those receiving 30 U/kg and + 2.3 (1.0) g/dL (+ 24.9% [10.6%], n = 3) for those receiving 60 U/kg. All 7 patients with anemia demonstrated improvement in Hb level throughout the study, and none had anemia at study end. In the patients who switched from imiglucerase, Hb levels improved or remained stable through 33 months of taliglucerase alfa treatment (Fig. 3b , Table 2 ). Mean platelet counts improved during 36 months of therapy with taliglucerase alfa in treatment-naïve patients (Fig. 3c, Table 2 ). Mean platelet counts were 182,000/mm 3 at baseline and 220,000/mm 3 at 36 months for patients receiving 30 U/kg and 99,600/mm 3 at baseline and 243,750/mm 3 at 36 months for patients receiving 60 U/kg. Some patients showed variation over time in platelet count (Fig. 3c) . In patients who switched from imiglucerase, mean platelet counts improved or remained stable during the 33 months of therapy with taliglucerase alfa (Fig. 3d, Table 2 ). Some variation over time was observed in platelet counts for individual patients (Fig. 3d) .
Biomarkers
In treatment-naïve patients, mean and individual chitotriosidase activity (Fig. 4a, Table 2 ) and chemokine (C-C motif) ligand 18 (CCL18) concentration (Fig. 4c, Table 2 ) improved over 36 months of treatment with taliglucerase alfa, with most of the improvement noted by 12 months. Mean (SE) percent changes in chitotriosidase activity and CCL18 concentration from baseline to 36 months were − 72.7% (7.3%) and − 67.7% (9.3%), respectively, in patients receiving 30 U/kg and −84.4% (6.6%) and −73.2% (7.9%), respectively, in patients receiving 60 U/kg. In patients who switched from imiglucerase, mean chitotriosidase activity and CCL18 concentration improved during taliglucerase alfa treatment, with some individual variation ( Fig. 4b  and d ).
Growth and development
With regard to growth and development, it may be worthwhile to note that the patients in the 60 U/kg dose group were somewhat younger overall (mean 6.6 years; range 2-10 years) than patients in the 30 U/kg dose group (mean 8.6 years; range 3-13 years) ( Table 1 ). All patients exhibited growth during this study. Mean (SE) percent change in height from baseline to 36 months was +12.4% (2.6%) with 30 U/kg (n = 4) and + 19.2% (3.0%) with 60 U/kg (n = 4) in treatment-naïve patients, and + 5.0% (3.1%) at 33 months in patients who switched from imiglucerase (n = 2). Analysis of height velocity through the end of the study (or last visit if a patient did not complete the study) revealed mean (SE) rates of 5.5 (0.8) cm/year with 30 U/kg (n = 5) and 6.7 (0.6) cm/year with 60 U/kg (n = 5) in treatmentnaïve patients and 2.5 (0.7) cm/year (n = 5) in patients who switched from imiglucerase. Mean (SE) percent change in weight from baseline to 36 months was 39.8% (4.6%) with 30 U/kg (n = 5) and 35.0% (3.6%) with 60 U/kg (n = 4) in treatment-naïve patients and 18.2% (8.8%) in patients who switched from imiglucerase (n = 2) after 33 months of treatment.
The pubertal status (assessed by Tanner stage) did not change during this extension study for most patients. All treatment-naive patients were ≤10 years of age at baseline; 9 patients were at stage 1 and 1 patient was at stage 3. Two patients treated with taliglucerase alfa 30 U/kg had pubertal advancement; 1 patient (91-5008) progressed from Tanner stage 1 at baseline to stage 2 by 12 months and continued to advance to stage 3 by the end of this study. The other patient (91-5009) advanced from Tanner stage 3 to stage 4 by 18 months. Two patients who switched from imiglucerase (14-229 and 14-230) advanced from Tanner stage 3 and 2, respectively, to stage 4 by the end of the study.
Bone age increased from baseline by a mean (SE) of 3.6 (0.9) years (range, 1.5-6.5 years) over the 36 months of the combined study for the 30 U/kg cohort (n = 5) and by 4.6 (0.6) years (range, 3.0-5.5 years) for the 60 U/kg cohort (n = 4) in treatment-naïve patients. For 3 patients who switched from imiglucerase and had baseline bone age measurements, bone age increased by a mean (SE) of 2.3 (0.3) years (range, 2.0-3.0 years) by 24 months (no data available over 33 months).
Quality of life was assessed in treatment-naïve patients. Findings from the Child Health Questionnaire™ Parent Form-28 showed that more parents/guardians rated their children's global health as "very good" at 36 months (7/9) than at baseline (1/9). Parental assessment of a child's global health improved from "fair" to "very good" for 3 patients and from "good" to "very good" for 3 patients. At baseline, 2 of 9 parents/guardians rated their children's health as "much better" or "somewhat better" than 1 year ago; at 36 months, 6 of 9 parents/guardians rated their children's health as "much better" or "somewhat better" than 1 year ago. At 36 months, 1 of 9 parents/guardians had "quite a bit" or "a lot" of worry about their children's physical health compared with 5 of 9 parents/guardians at baseline. Furthermore, at 36 months, 1 of 9 parents/guardians said they were limited a lot in the amount of time available for their own needs compared with 3 of 9 parents/guardians at baseline.
Safety
Taliglucerase alfa treatment was well tolerated. All AEs were mild to moderate in severity ( Table 3 ). The most common AEs (≥3 of 15 total patients) reported during extension study PB-06-006 were cough (n = 4), headache (n = 4), upper respiratory tract infection (n = 4), abdominal pain (n = 3), Dengue fever (n = 3), diarrhea (n = 3), lymphedema (n = 3), nasopharyngitis (n = 3), and pain in extremity (n = 3). No patient had a change to his/her taliglucerase alfa dose because of an AE. One AE was assessed as possibly related to study drug (Table 3) ; this event was mild (Grade 1) infusion site pain in a treatment-naïve patient (11-5004; 60 U/kg) and resolved on the same day. No deaths occurred during the study, and no patients were discontinued from the study because of an AE. One serious AE occurred (Table 3 ), a case of Grade 2 Dengue fever requiring hospitalization in a treatment-naïve patient ; the event resolved within 5 weeks and was considered not to be related to study drug. Most laboratory hematology and biochemistry parameters remained at normal levels at the end of the study, and there were no clinically meaningful laboratory abnormalities. No patient experienced a bone crisis during the extension study.
Immunogenicity
No episodes of anaphylaxis occurred during study PB-06-006. Of the treatment-naive patients who tested positive for the presence of antitaliglucerase alfa IgG antibodies during PB-06-005, 1 patient (91-5009; 30 U/kg) remained antibody-positive through extension study PB-06-006 and tested positive for neutralizing antibodies based on the in vitro enzymatic activity assay. For this patient, spleen and liver volumes, Hb levels, platelet counts, chitotriosidase activity, and CCL18 levels continued to improve through the 36 months of taliglucerase alfa treatment. Four weeks into the extension study, the patient was diagnosed with Dengue fever; the event was considered mild in severity, resolved within 2 days, and was not considered by the investigator to be related to treatment. All 5 patients who switched from imiglucerase tested negative for anti-taliglucerase alfa IgG antibodies during the extension study.
Type 3 GD
Two children in this extension study had Type 3 GD, 1 treatmentnaïve patient and 1 switched from imiglucerase. Patient 10-5002 (30 U/kg) was 3 years old at entry into the parent study (PB-06-005) and continued into the extension study, completing 36 total months of treatment. Although the patient did not have an organ volume measurement during the extension study because sedation was not permitted during MRI evaluations at the patient's study site, measurements made at the end of the preceding study indicated that spleen volume decreased from 9.0 to 7.1 MN and liver volume decreased from 1.4 to 1.2 MN by 12 months (end of study PB-06-005). At 36 months, his Hb level increased to 12.8 mg/dL from a baseline of 12.2 mg/dL and platelet count increased to 153,000/mm 3 from a baseline of 145,000/mm 3 ;
chitotriosidase activity decreased 57% and CCL18 decreased by 41% from baseline. The patient experienced 10 mild AEs during the extension study, none of which was considered to be treatment-related. He had normal echocardiography and none of his laboratory results were clinically significant or reported as an AE. Patient 92-232 was a 6-year-old male at entry into original study PB-06-002 and continued into the extension study, completing 27 total months of treatment before entering a compassionate use program for taliglucerase alfa. The patient was diagnosed by his physician as having Type 1 GD, but was homozygous for the c.1448TNC (L444P) mutation in the GBA gene, suggesting that he has Type 3 GD, although during the time of the clinical trials, neurologic findings had not been noted. At the time of last observation, spleen volume decreased from 7.9 MN at baseline to 5.6 MN, liver volume decreased from 1.6 MN at baseline to 1.3 MN, Hb level increased from 12.9 mg/dL at baseline to 13.1 mg/dL, chitotriosidase activity decreased 43%, and CCL18 decreased by 23% from baseline. Platelet count had increased from 140,000/mm 3 to 282,000/mm 3 by 24 total months of treatment but was 132,000/mm 3 at last observation. The patient experienced 12 mild AEs during the extension study, none of which was considered to be treatment-related. Exclusion of the data from these 2 patients from safety and efficacy analyses did not significantly affect the results of this extension study (data not shown).
Discussion
This study extends the safety and efficacy findings of taliglucerase alfa from PB-06-005, a study notable for its sole focus on pediatric patients with GD [11] and provides longer term data on the pediatric patients from PB-06-002 who were switched from imiglucerase to taliglucerase alfa [12] . Treatment with taliglucerase alfa 30 or 60 U/kg resulted in continuous improvements in visceral and hematologic disease parameters and biomarkers through 36 total months in treatment-naïve children and was similar to that shown in adult patients with GD; stability of visceral and hematologic disease parameters and biomarkers was maintained during 33 months of treatment with taliglucerase alfa in the cohort of children who switched from imiglucerase.
Improvements in visceral and hematologic manifestations of GD demonstrated by pediatric patients receiving long-term therapy with taliglucerase alfa in this study were consistent with those observed for adult and pediatric patients with GD receiving long-term treatment with imiglucerase and velaglucerase alfa in other studies [16, 17] . Efficacy and safety findings for pediatric patients were also similar to those for adults with GD receiving long-term therapy with taliglucerase alfa [18, 19] .
Anemia is common in children with GD, affecting ≈40% of patients, and tends to be more severe in patients who present at the youngest ages [7] . Anemia in patients with GD has been largely attributed to hypersplenism and replacement of bone marrow by Gaucher cells [1, 2] , which may contribute to fatigue and weakness and may necessitate blood transfusions [5] . Seven of the 10 treatment-naïve patients had anemia at baseline; by study end, the anemia had resolved in all 7 patients. Aspects of GD unique to pediatric patients include growth inhibition and pubertal delay [3] [4] [5] [6] [7] 20] . Exploratory analyses looked at the effects of taliglucerase alfa on growth, pubertal development (treatment-naïve patients only), and bone age. All patients continued to grow and increase in height and weight during the study, and assessments of mean bone age and pubertal status also showed improvement. Bone disease in patients with GD can start as early in childhood as 5 years [20] , and progressive skeletal pathology in patients with GD is highly debilitating [2] . As noted in the results, none of the patients in the extension study experienced a bone crisis. The findings from this study extend the safety profile observed in pediatric patients receiving taliglucerase alfa, which were similar to those in the original studies (PB-06-005 and PB-06-002) [11, 12] . Treatment was generally well tolerated. No severe AEs occurred, no serious, treatment-related AEs were observed, and no patients discontinued because of an AE. There were no differences in the safety profile for the 30 U/kg and 60 U/kg doses in this extension study. Although some patients tested positive for anti-taliglucerase alfa antibodies at different points in PB-06-005 and PB-06-002, only 1 patient (91-5009) tested positive during the extension study (months 18, 24, 30, and 36); however, this patient demonstrated continuous improvement from baseline in hematologic parameters, organ volumes, and biomarkers through 36 months of treatment. The sustained improvement in the treatmentnaïve patients and maintained stability of disease parameters in patients who switched from imiglucerase suggest a lack of substantial impact of the positive anti-taliglucerase alfa antibody results on treatment efficacy.
This study included 2 patients with Type 3 GD (10-5002 and 92-232). In general, these patients experienced improvements in the visceral, hematologic, and biomarker parameters assessed. Sensitivity analyses demonstrated that inclusion of these patients had no significant impact on the long-term efficacy and safety analyses of patients with Type 1 GD. Other sensitivity analyses demonstrated that patient discontinuations had no significant impact on the long-term efficacy and safety findings.
ERT is a standard of care for the non-neuronopathic features of Type 3 GD [21] . The European Working Group on Gaucher Disease recommends that ERT be initiated as soon as possible for patients with Type 3 GD because of documented clinical improvements in visceral, hematologic, and skeletal disease manifestations [22] . However, the only country to date in which taliglucerase alfa is approved for Type 3 GD is Canada. Because of the restriction of approved use to Type 1 GD, patients in many countries encounter difficulties in obtaining reimbursement for treatment costs.
Taliglucerase alfa does is not approved in the European Union despite a positive risk-benefit assessment by the European Medicines Agency because that body granted orphan drug status and marketing exclusivity to velaglucerase alfa, another ERT for GD, in 2010. Taliglucerase alfa was approved by the US Food and Drug Administration on the basis of 2 pivotal studies that primarily enrolled adult patients; of these, 1 study (PB-06-002) enrolled 5 pediatric patients following a protocol amendment.
Interpretation of these study findings is limited by the small number of patients, which precluded analysis of variance of changes from baseline and comparisons between doses. This ERT study is unique in that it focuses exclusively on pediatric patients with GD. Positive results found in the study are highly consistent with the body of data from N20 years of clinical research showing that pediatric and adult patients with Type 1 GD respond similarly to ERT.
In this extension study, taliglucerase alfa therapy administered to 15 pediatric patients with GD demonstrated improvements in visceral and hematologic parameters and in biomarkers in treatment-naïve patients and maintenance of disease stability in patients switched from imiglucerase to taliglucerase alfa. Treatment was well tolerated, and no new safety signals emerged.
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